Back to search results

Non-small Cell Lung Cancer

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

JPBJ | {{ defaultRegistry.registryAnchorText }} NCT02079636 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.

Completed Study

The results of this study are not yet available.

Time Commitment

Depending on how you and your tumor respond to treatment, your study participation could last until your disease worsens or until you and your doctor decide to stop treatment.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study


Male Female


18+ years
  • Participant must have stage IV non-small cell lung cancer (NSCLC)
  • Part D, US only participants (any subtype) must have received at least two, but not more than three prior therapies for advanced/metastatic NSCLC. The participant must not have received prior treatment with any phosphoinositide 3-kinase (PI3K) or mammalian target of rapamycin (mTOR) inhibitor
  • Part E Participant (any subtype) must have received at least one but no more than three prior therapies for advanced/metastatic NSCLC
  • Male and female participants of reproductive potential must agree to use medically approved contraceptive precautions during the trial and 3 to 4 months (as appropriate) following last dose of study drug
  • Participant must be able to swallow oral medications
  • Participant must not have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix or breast), unless in complete remission with no therapy for a minimum of 3 years
  • Participant must not be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial

Where This Study Took Place Tool Tip Icon

Where This Study Took Place Tool Tip Icon

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.